The Implications and Future Perspectives of Nanomedicine for Cancer Stem Cell Targeted Therapies

Cancer stem cells (CSCs) are believed to exhibit distinctive self-renewal, proliferation, and differentiation capabilities, and thus play a significant role in various aspects of cancer. CSCs have significant impacts on the progression of tumors, drug resistance, recurrence and metastasis in different types of malignancies. Due to their primary role, most researchers have focused on developing anti-CSC therapeutic strategies, and tremendous efforts have been put to explore methods for selective eradication of these therapeutically resistant CSCs. In recent years, many reports have shown the use of CSCs-specific approaches such as ATP-binding cassette (ABC) transporters, blockade of self-renewal and survival of CSCs, CSCs surface markers targeted drugs delivery and eradication of the tumor microenvironment. Also, various therapeutic agents such as small molecule drugs, nucleic acids, and antibodies are said to destroy CSCs selectively. Targeted drug delivery holds the key to the success of most of the anti-CSCs based drugs/therapies. The convention CSCs-specific therapeutic agents, suffer from various problems. For instance, limited water solubility, small circulation time and inconsistent stability of conventional therapeutic agents have significantly limited their efficacy. Recent advancement in the drug delivery technology has demonstrated that specially designed nanocarrier-based drug delivery approaches (nanomedicine) can be useful in delivering sufficient amount of drug molecules even in the most interiors of CSCs niches and thus can overcome the limitations associated with the conventional free drug delivery methods. The nanomedicine has also been promising in designing effective therapeutic regime against pump-mediated drug resistance (ATP-driven) and reduces detrimental effects on normal stem cells. Here we focus on the biological processes regulating CSCs' drug resistance and various strategies developed so far to deal with them. We also review the various nanomedicine approaches developed so far to overcome these CSCs related issues and their future perspectives.

[1]  R. Patel,et al.  Ganciclovir Loaded Chitosan Nanoparticles: Preparation andCharacterization , 2016 .

[2]  B. Wagner,et al.  Aggregation enhanced excimer emission (AEEE) with efficient blue emission based on pyrene dendrimers , 2016 .

[3]  Jun Wang,et al.  Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[4]  A. Chang,et al.  Concise Reviews : Targeting Cancer Stem Cells Using Immunologic Approaches , 2015 .

[5]  Yan‐Hua Zhu,et al.  Delivery of bortezomib with nanoparticles for basal-like triple-negative breast cancer therapy. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[6]  Xiongbin Lu,et al.  Chitosan-Decorated Doxorubicin-Encapsulated Nanoparticle Targets and Eliminates Tumor Reinitiating Cancer Stem-like Cells. , 2015, ACS nano.

[7]  Michael T. McManus,et al.  Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR. , 2015, Molecular cell.

[8]  Hong-Xia Wang,et al.  Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[9]  Yan‐Hua Zhu,et al.  Targeting glucose uptake with siRNA-based nanomedicine for cancer therapy. , 2015, Biomaterials.

[10]  Takashi Yamamoto,et al.  Cloning-free CRISPR/Cas system facilitates functional cassette knock-in in mice , 2015, Genome Biology.

[11]  Michael S. Goldberg,et al.  Immunoengineering: How Nanotechnology Can Enhance Cancer Immunotherapy , 2015, Cell.

[12]  L. A. Raj,et al.  Biosynthesis and Characterization of Zinc Oxide Nanoparticles using Root Extract of Zingiber officinale , 2015 .

[13]  C. Hadjipanayis,et al.  Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles , 2015, Oncotarget.

[14]  Z. Werb,et al.  The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? , 2015, Cell stem cell.

[15]  Alexandra Flemming Cancer stem cells: Targeting the root of cancer relapse , 2015, Nature Reviews Drug Discovery.

[16]  Randall J. Platt,et al.  Therapeutic genome editing: prospects and challenges , 2015, Nature Medicine.

[17]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[18]  H. A. Rogoff,et al.  Suppression of cancer relapse and metastasis by inhibiting cancer stemness , 2015, Proceedings of the National Academy of Sciences.

[19]  Kenneth L. Jones,et al.  Autophagy Supports Breast Cancer Stem Cell Maintenance by Regulating IL6 Secretion , 2015, Molecular Cancer Research.

[20]  U. Domańska,et al.  PLGA Biodegradable Nanoparticles Containing Perphenazine or Chlorpromazine Hydrochloride: Effect of Formulation and Release , 2014, International journal of molecular sciences.

[21]  Youqing Shen,et al.  Integration of Nanoassembly Functions for an Effective Delivery Cascade for Cancer Drugs , 2014, Advanced materials.

[22]  Dong Choon Hyun,et al.  Engineered nanoparticles for drug delivery in cancer therapy. , 2014, Angewandte Chemie.

[23]  J. Sunwoo,et al.  PD-L1 is preferentially expressed on CD44+ tumor-initiating cells in head and neck squamous cell carcinoma , 2014, Journal of Immunotherapy for Cancer.

[24]  H. Uludaǧ,et al.  Polymeric nanoparticle-mediated silencing of CD44 receptor in CD34+ acute myeloid leukemia cells. , 2014, Leukemia research.

[25]  Yingge Zhang,et al.  The effect of hyaluronic acid functionalized carbon nanotubes loaded with salinomycin on gastric cancer stem cells. , 2014, Biomaterials.

[26]  Yi Yan Yang,et al.  Phenformin-loaded polymeric micelles for targeting both cancer cells and cancer stem cells in vitro and in vivo. , 2014, Biomaterials.

[27]  J. Keith Joung,et al.  Efficient Delivery of Genome-Editing Proteins In Vitro and In Vivo , 2014, Nature Biotechnology.

[28]  You-hong Cui,et al.  Metastatic consequences of immune escape from NK cell cytotoxicity by human breast cancer stem cells. , 2014, Cancer research.

[29]  J. Wolchok,et al.  Immune modulation for cancer therapy , 2014, British Journal of Cancer.

[30]  S. Carr,et al.  A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages , 2014, Nature Cell Biology.

[31]  Robert Langer,et al.  CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling , 2014, Cell.

[32]  A. Akbarzadeh,et al.  Carbon nanotubes: properties, synthesis, purification, and medical applications , 2014, Nanoscale Research Letters.

[33]  Jun Wang,et al.  Matrix metalloproteinase 2-responsive micelle for siRNA delivery. , 2014, Biomaterials.

[34]  Yong Ren,et al.  Recent advances in nanoparticle-mediated siRNA delivery. , 2014, Annual review of biomedical engineering.

[35]  S. Chellappan,et al.  Cationic lipid guided short-hairpin RNA interference of annexin A2 attenuates tumor growth and metastasis in a mouse lung cancer stem cell model. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[36]  Jayanta Bhattacharyya,et al.  iTEP Nanoparticle-Delivered Salinomycin Displays an Enhanced Toxicity to Cancer Stem Cells in Orthotopic Breast Tumors , 2014, Molecular pharmaceutics.

[37]  X. Qian,et al.  Enhancement of radiotherapy efficacy by miR-200c-loaded gelatinase-stimuli PEG-Pep-PCL nanoparticles in gastric cancer cells , 2014, International journal of nanomedicine.

[38]  John A. Dagata,et al.  A Nanoparticle Carrying the p53 Gene Targets Tumors Including Cancer Stem Cells, Sensitizes Glioblastoma to Chemotherapy and Improves Survival , 2014, ACS nano.

[39]  S. Venkatraman,et al.  Layer-by-layer nanoparticles as an efficient siRNA delivery vehicle for SPARC silencing. , 2014, Small.

[40]  Tao Zhang,et al.  Targeting cancer stem cells by curcumin and clinical applications. , 2014, Cancer letters.

[41]  M. Hidalgo,et al.  Chloroquine Targets Pancreatic Cancer Stem Cells via Inhibition of CXCR4 and Hedgehog Signaling , 2014, Molecular Cancer Therapeutics.

[42]  Eduard Batlle,et al.  Metastatic stem cells: sources, niches, and vital pathways. , 2014, Cell stem cell.

[43]  Jin-Zhi Du,et al.  Surface-modulated and thermoresponsive polyphosphoester nanoparticles for enhanced intracellular drug delivery , 2014, Science China Chemistry.

[44]  Pu Xia Surface markers of cancer stem cells in solid tumors. , 2014, Current stem cell research & therapy.

[45]  Lin Mei,et al.  Co-delivery of chemotherapeutic drugs with vitamin E TPGS by porous PLGA nanoparticles for enhanced chemotherapy against multi-drug resistance. , 2014, Biomaterials.

[46]  G. Parmiani,et al.  Immunology of cancer stem cells in solid tumours. A review. , 2014, European journal of cancer.

[47]  Louis M Weiner,et al.  The clinical potential of targeted nanomedicine: delivering to cancer stem-like cells. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[48]  Jian Huang,et al.  The cancer stem cell niche: cross talk between cancer stem cells and their microenvironment , 2014, Tumor Biology.

[49]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[50]  J. Rhim,et al.  HPMA copolymer-based combination therapy toxic to both prostate cancer stem/progenitor cells and differentiated cells induces durable anti-tumor effects. , 2013, Journal of Controlled Release.

[51]  Dong Wang,et al.  Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts , 2013, Stem cell reports.

[52]  Yoav D Livney,et al.  Rationally designed nanovehicles to overcome cancer chemoresistance. , 2013, Advanced drug delivery reviews.

[53]  J. Ljubimova,et al.  Nanomedicine therapeutic approaches to overcome cancer drug resistance. , 2013, Advanced drug delivery reviews.

[54]  Alexander V Kabanov,et al.  Can nanomedicines kill cancer stem cells? , 2013, Advanced drug delivery reviews.

[55]  David Baker,et al.  megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering , 2013, Nucleic acids research.

[56]  J. Panyam,et al.  CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[57]  Feng Zhang,et al.  Genome engineering using CRISPR-Cas9 system. , 2015, Methods in molecular biology.

[58]  C. Thaxton,et al.  Update on current and potential nanoparticle cancer therapies , 2013, Current opinion in oncology.

[59]  Patrick Couvreur,et al.  Stimuli-responsive nanocarriers for drug delivery. , 2013, Nature materials.

[60]  Young Seob Kim,et al.  Nanoparticle-Based Vaccine Delivery for Cancer Immunotherapy , 2013, Immune network.

[61]  Z. Huang,et al.  Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment , 2013, Cell Death and Disease.

[62]  Lin Zheng,et al.  Development of a gene/drug dual delivery system for brain tumor therapy: potent inhibition via RNA interference and synergistic effects. , 2013, Biomaterials.

[63]  Duxin Sun,et al.  The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel. , 2013, Biomaterials.

[64]  C. Blanpain,et al.  Unravelling cancer stem cell potential , 2013, Nature Reviews Cancer.

[65]  Corbin E. Meacham,et al.  Tumour heterogeneity and cancer cell plasticity , 2013, Nature.

[66]  Andrew E. Sloan,et al.  Brain Tumor Initiating Cells Adapt to Restricted Nutrition through Preferential Glucose Uptake , 2013, Nature Neuroscience.

[67]  Jia Wei,et al.  Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles. , 2013, Biomaterials.

[68]  C. Cho,et al.  Nanoparticle-mediated delivery of therapeutic genes: focus on miRNA therapeutics , 2013, Expert opinion on drug delivery.

[69]  Z. Cui,et al.  Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles. , 2013, Molecular pharmaceutics.

[70]  L. Pfeffer,et al.  Constitutive Activation of Signal Transducer and Activator of Transcription 3 (STAT3) and Nuclear Factor κB Signaling in Glioblastoma Cancer Stem Cells Regulates the Notch Pathway* , 2013, The Journal of Biological Chemistry.

[71]  C. Drake,et al.  Molecular Pathways Molecular Pathways : Coexpression of Immune Checkpoint Molecules : Signaling Pathways and Implications for Cancer Immunotherapy , 2013 .

[72]  Ke Chen,et al.  Understanding and targeting cancer stem cells: therapeutic implications and challenges , 2013, Acta Pharmacologica Sinica.

[73]  M. Toda Glioma Stem Cells and Immunotherapy for the Treatment of Malignant Gliomas , 2013, ISRN oncology.

[74]  Giovanni Broggi,et al.  CD133 Is Essential for Glioblastoma Stem Cell Maintenance , 2013, Stem cells.

[75]  S. Vinogradov,et al.  Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors. , 2013, Bioconjugate chemistry.

[76]  Tao Gong,et al.  Systemic delivery of microRNA-34a for cancer stem cell therapy. , 2013, Angewandte Chemie.

[77]  E. Cuyás,et al.  The Warburg effect version 2.0: Metabolic reprogramming of cancer stem cells , 2013, Cell cycle.

[78]  Say Chye Joachim Loo,et al.  One-step fabrication of core-shell structured alginate-PLGA/PLLA microparticles as a novel drug delivery system for water soluble drugs. , 2013, Biomaterials science.

[79]  Jan Paul Medema,et al.  Cancer stem cells: The challenges ahead , 2013, Nature Cell Biology.

[80]  Arun K Iyer,et al.  Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. , 2013, Biomaterials.

[81]  J. Taube,et al.  Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. , 2013, Cancer research.

[82]  Chen Jiang,et al.  Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis. , 2013, ACS nano.

[83]  Jessica M. Rusert,et al.  A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. , 2013, Cell stem cell.

[84]  A. Loubat,et al.  Preventive Cancer Stem Cell‐Based Vaccination Reduces Liver Metastasis Development in a Rat Colon Carcinoma Syngeneic Model , 2013, Stem cells.

[85]  Luke A. Gilbert,et al.  Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression , 2013, Cell.

[86]  C. Jamieson,et al.  Therapeutics against Cancer Stem Cells: Targeting the Root of Cancer , 2013 .

[87]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[88]  G. Sambuceti,et al.  Metformin selectively affects human glioblastoma tumor-initiating cell viability , 2013, Cell Cycle.

[89]  K. Struhl,et al.  Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth , 2012, Proceedings of the National Academy of Sciences.

[90]  F. Wang,et al.  Octamer 4 Small Interfering RNA Results in Cancer Stem Cell-Like Cell Apoptosis , 2012 .

[91]  V. Muzykantov,et al.  Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities , 2012, Science.

[92]  Jun Wang,et al.  Surface Charge Switchable Nanoparticles Based on Zwitterionic Polymer for Enhanced Drug Delivery to Tumor , 2012, Advanced materials.

[93]  A. Meeson,et al.  Breast cancer, side population cells and ABCG2 expression. , 2012, Cancer letters.

[94]  Zibin Gao,et al.  Nanotechnology applied to overcome tumor drug resistance. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[95]  Hefen Sun,et al.  BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocellular carcinoma. , 2012, Cancer research.

[96]  Jian Huang,et al.  Novel micelle formulation of curcumin for enhancing antitumor activity and inhibiting colorectal cancer stem cells , 2012, International journal of nanomedicine.

[97]  Hans Clevers,et al.  Lineage Tracing Reveals Lgr5+ Stem Cell Activity in Mouse Intestinal Adenomas , 2012, Science.

[98]  Benjamin D. Simons,et al.  Defining the mode of tumour growth by clonal analysis , 2012, Nature.

[99]  Erkki Ruoslahti,et al.  Peptides as Targeting Elements and Tissue Penetration Devices for Nanoparticles , 2012, Advanced materials.

[100]  Weijun Su,et al.  CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma. , 2012, Biomaterials.

[101]  F. Bertucci,et al.  Mevalonate Metabolism Regulates Basal Breast Cancer Stem Cells and Is a Potential Therapeutic Target , 2012, Stem cells.

[102]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[103]  Y. Barenholz Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[104]  B. Leber,et al.  Identification of Drugs Including a Dopamine Receptor Antagonist that Selectively Target Cancer Stem Cells , 2012, Cell.

[105]  J. Datta,et al.  Lipid-based nanoparticle delivery of Pre-miR-107 inhibits the tumorigenicity of head and neck squamous cell carcinoma. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[106]  Guang-Yuh Chiou,et al.  Nuclear localization signal-enhanced RNA interference of EZH2 and Oct4 in the eradication of head and neck squamous cell carcinoma-derived cancer stem cells. , 2012, Biomaterials.

[107]  Guang-Yuh Chiou,et al.  Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial-mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[108]  S. Vinogradov,et al.  Cancer stem cells and drug resistance: the potential of nanomedicine. , 2012, Nanomedicine.

[109]  A. Chang,et al.  Cancer stem cell vaccination confers significant antitumor immunity. , 2012, Cancer research.

[110]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[111]  P. Ward,et al.  Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. , 2012, Cancer cell.

[112]  G. Wahl,et al.  Stem cells, cancer, and cancer stem cells , 2012 .

[113]  Yang-Hsin Shih,et al.  Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. , 2012, Biomaterials.

[114]  J. Kopeček,et al.  Selective inhibitory effect of HPMA copolymer-cyclopamine conjugate on prostate cancer stem cells. , 2012, Biomaterials.

[115]  Peter Dirks,et al.  Cancer stem cells: an evolving concept , 2012, Nature Reviews Cancer.

[116]  F. Qiu,et al.  Oxaliplatin-incorporated micelles eliminate both cancer stem-like and bulk cell populations in colorectal cancer , 2011, International journal of nanomedicine.

[117]  Wenzhuo Zhuang,et al.  Induction of autophagy promotes differentiation of glioma‐initiating cells and their radiosensitivity , 2011, International journal of cancer.

[118]  M. Uesaka,et al.  Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. , 2011, Nature nanotechnology.

[119]  B. Martín-Castillo,et al.  Autophagy positively regulates the CD44+CD24-/low breast cancer stem-like phenotype , 2011, Cell cycle.

[120]  J. Wolchok,et al.  Novel cancer immunotherapy agents with survival benefit: recent successes and next steps , 2011, Nature Reviews Cancer.

[121]  P. Carmeliet,et al.  A vascular niche and a VEGF–Nrp1 loop regulate the initiation and stemness of skin tumours , 2011, Nature.

[122]  Jin-Zhi Du,et al.  Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery. , 2011, Journal of the American Chemical Society.

[123]  Max S Wicha,et al.  Breast cancer stem cells, cytokine networks, and the tumor microenvironment. , 2011, The Journal of clinical investigation.

[124]  W. Woodward,et al.  BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. , 2011, Cancer cell.

[125]  Daniel G. Anderson,et al.  Therapeutic siRNA silencing in inflammatory monocytes , 2011, Nature Biotechnology.

[126]  R. Ferris,et al.  Targeting ALDHbright Human Carcinoma–Initiating Cells with ALDH1A1-Specific CD8+ T Cells , 2011, Clinical Cancer Research.

[127]  Jesse V Jokerst,et al.  Nanoparticle PEGylation for imaging and therapy. , 2011, Nanomedicine.

[128]  Bo Yu,et al.  MicroRNA delivery by cationic lipoplexes for lung cancer therapy. , 2011, Molecular pharmaceutics.

[129]  P. Steeg,et al.  Notch1 Inhibition Alters the CD44hi/CD24lo Population and Reduces the Formation of Brain Metastases from Breast Cancer , 2011, Molecular Cancer Research.

[130]  Ick Chan Kwon,et al.  Tumor-homing photosensitizer-conjugated glycol chitosan nanoparticles for synchronous photodynamic imaging and therapy based on cellular on/off system. , 2011, Biomaterials.

[131]  Y. Bae,et al.  Prevention of metastasis in a 4T1 murine breast cancer model by doxorubicin carried by folate conjugated pH sensitive polymeric micelles. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[132]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[133]  A. Maitra,et al.  A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors , 2011, Cancer biology & therapy.

[134]  R. Zhuo,et al.  Dual-vectors of anti-cancer drugs and genes based on pH-sensitive micelles self-assembled from hybrid polypeptide copolymers , 2011 .

[135]  S. Ivy,et al.  Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways , 2011, Nature Reviews Clinical Oncology.

[136]  K. Kelnar,et al.  The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. , 2011, Nature medicine.

[137]  Elo Leung,et al.  A TALE nuclease architecture for efficient genome editing , 2011, Nature Biotechnology.

[138]  I. Ng,et al.  miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. , 2010, Cell stem cell.

[139]  Z. Chen Small-molecule delivery by nanoparticles for anticancer therapy. , 2010, Trends in molecular medicine.

[140]  S. Morrison,et al.  Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. , 2010, Cancer cell.

[141]  Erin L. Doyle,et al.  Targeting DNA Double-Strand Breaks with TAL Effector Nucleases , 2010, Genetics.

[142]  K. Mimori,et al.  CD13 is a therapeutic target in human liver cancer stem cells. , 2010, The Journal of clinical investigation.

[143]  U. Schubert,et al.  Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. , 2010, Angewandte Chemie.

[144]  Alfredo Quiñones-Hinojosa,et al.  Oxygen in stem cell biology: a critical component of the stem cell niche. , 2010, Cell stem cell.

[145]  Gaurav Sahay,et al.  Endocytosis of nanomedicines. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[146]  J. Angelastro,et al.  Overexpression of CD133 Promotes Drug Resistance in C6 Glioma Cells , 2010, Molecular Cancer Research.

[147]  A. Merchant,et al.  Targeting Hedgehog — a Cancer Stem Cell Pathway , 2010, Clinical Cancer Research.

[148]  Michael Kahn,et al.  Targeting Wnt Signaling: Can We Safely Eradicate Cancer Stem Cells? , 2010, Clinical Cancer Research.

[149]  T. Golde,et al.  Targeting Notch to Target Cancer Stem Cells , 2010, Clinical Cancer Research.

[150]  Christine Allen,et al.  The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. , 2010, Molecular pharmaceutics.

[151]  Louis Vermeulen,et al.  Wnt activity defines colon cancer stem cells and is regulated by the microenvironment , 2010, Nature Cell Biology.

[152]  Tao Zhang,et al.  Sulforaphane, a Dietary Component of Broccoli/Broccoli Sprouts, Inhibits Breast Cancer Stem Cells , 2010, Clinical Cancer Research.

[153]  Z. Werb,et al.  Matrix Metalloproteinases: Regulators of the Tumor Microenvironment , 2010, Cell.

[154]  Charles P. Lin,et al.  Bone progenitor dysfunction induces myelodysplasia and secondary leukemia , 2010, Nature.

[155]  Vincent M. Rotello,et al.  Tuning Payload Delivery in Tumour Cylindroids using Gold Nanoparticles , 2010, Nature nanotechnology.

[156]  C. Brennan,et al.  Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. , 2010, Cell stem cell.

[157]  J. Dumont,et al.  Cancer stem cells: a reality, a myth, a fuzzy concept or a misnomer? An analysis. , 2010, Carcinogenesis.

[158]  D. Birnbaum,et al.  CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. , 2010, The Journal of clinical investigation.

[159]  F. Hodi,et al.  Tumor and Stem Cell Biology Cancer Research Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells , 2010 .

[160]  P. Pelicci,et al.  Biological and Molecular Heterogeneity of Breast Cancers Correlates with Their Cancer Stem Cell Content , 2010, Cell.

[161]  David A. Gough,et al.  Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[162]  N. Clarke,et al.  Hoechst 33342 side population identification is a conserved and unified mechanism in urological cancers. , 2009, Stem cells and development.

[163]  Kevin Struhl,et al.  Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. , 2009, Cancer research.

[164]  L. Mariani,et al.  Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment , 2009, Proceedings of the National Academy of Sciences.

[165]  Michael F. Clarke,et al.  Downregulation of miRNA-200c Links Breast Cancer Stem Cells with Normal Stem Cells , 2009, Cell.

[166]  Eric S. Lander,et al.  Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening , 2009, Cell.

[167]  J. Dick,et al.  Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. , 2009, Cell stem cell.

[168]  Xian‐Zheng Zhang,et al.  Temperature‐ and pH‐Sensitive Multicolored Micellar Complexes , 2009 .

[169]  Hui Wang,et al.  Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. , 2009, Cancer cell.

[170]  Ick Chan Kwon,et al.  New Generation of Multifunctional Nanoparticles for Cancer Imaging and Therapy , 2009 .

[171]  Irving L. Weissman,et al.  Association of reactive oxygen species levels and radioresistance in cancer stem cells , 2009, Nature.

[172]  B. Stiles,et al.  Expansion of CD133‐Expressing Liver Cancer Stem Cells in Liver‐Specific Phosphatase and Tensin Homolog Deleted on Chromosome 10‐Deleted Mice , 2009, Stem cells.

[173]  John J. Rossi,et al.  The promises and pitfalls of RNA-interference-based therapeutics , 2009, Nature.

[174]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[175]  P. McCarron,et al.  Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells. , 2008, Bioconjugate chemistry.

[176]  Yang Liu,et al.  A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[177]  S. Salati,et al.  Signal control of hematopoietic stem cell fate: Wnt, Notch, and Hedgehog as the usual suspects , 2008, Current opinion in hematology.

[178]  M. Clarke,et al.  Colorectal Cancer Stem Cells Are Enriched in Xenogeneic Tumors Following Chemotherapy , 2008, PloS one.

[179]  M. Mullendore,et al.  Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer , 2008, Gut.

[180]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[181]  X. Guan,et al.  CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway , 2008, Oncogene.

[182]  M. Biffoni,et al.  Identification and expansion of the tumorigenic lung cancer stem cell population , 2008, Cell Death and Differentiation.

[183]  S. Fan,et al.  Significance of CD90+ cancer stem cells in human liver cancer. , 2008, Cancer cell.

[184]  Mohamed H. Sayegh,et al.  Identification of cells initiating human melanomas , 2008, Nature.

[185]  M. Frank,et al.  Cancer stem cells and human malignant melanoma , 2007, Pigment Cell & Melanoma Research.

[186]  J. Lieberman,et al.  let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells , 2007, Cell.

[187]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[188]  O. Ringdén,et al.  Immunomodulation by mesenchymal stem cells and clinical experience , 2007, Journal of internal medicine.

[189]  M. Todaro,et al.  Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. , 2007, Cell stem cell.

[190]  J. Margolick,et al.  Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance , 2007, Proceedings of the National Academy of Sciences.

[191]  R. Bellamkonda,et al.  Decreased circulation time offsets increased efficacy of PEGylated nanocarriers targeting folate receptors of glioma , 2007 .

[192]  Alicia Zhou,et al.  Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers , 2007, Proceedings of the National Academy of Sciences.

[193]  Héctor Peinado,et al.  Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? , 2007, Nature Reviews Cancer.

[194]  Stephen Lam,et al.  Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. , 2007, Cancer research.

[195]  Brian Keith,et al.  Hypoxia-Inducible Factors, Stem Cells, and Cancer , 2007, Cell.

[196]  Fariba Behbod,et al.  Correction for Woodward et al., WNT/β-catenin mediates radiation resistance of mouse mammary progenitor cells , 2007, Proceedings of the National Academy of Sciences.

[197]  G. Z. Cheng,et al.  Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. , 2007, Cancer research.

[198]  J. Dick,et al.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice , 2007, Nature.

[199]  L. Ricci-Vitiani,et al.  Identification and expansion of human colon-cancer-initiating cells , 2007, Nature.

[200]  M. Diehn,et al.  Cancer stem cells and radiotherapy: new insights into tumor radioresistance. , 2006, Journal of the National Cancer Institute.

[201]  Anne E Carpenter,et al.  The Spemann organizer gene, Goosecoid, promotes tumor metastasis , 2006, Proceedings of the National Academy of Sciences.

[202]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[203]  P. Duchateau,et al.  A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences , 2006, Nucleic acids research.

[204]  J. Dick,et al.  Targeting of CD44 eradicates human acute myeloid leukemic stem cells , 2006, Nature Medicine.

[205]  Qiulian Wu,et al.  Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. , 2006, Cancer research.

[206]  L. Ricci-Vitiani,et al.  Chemotherapy resistance of glioblastoma stem cells , 2006, Cell Death and Differentiation.

[207]  E. Mini,et al.  Pharmacological strategies for overcoming multidrug resistance. , 2006, Current drug targets.

[208]  T. Wu,et al.  Prospects of RNA interference therapy for cancer , 2006, Gene Therapy.

[209]  K. Briegel Embryonic transcription factors in human breast cancer , 2006, IUBMB life.

[210]  P. Dalerba,et al.  Identification of pancreatic cancer stem cells. , 2006, Cancer research.

[211]  Rolf Bjerkvig,et al.  The origin of the cancer stem cell: current controversies and new insights , 2005, Nature Reviews Cancer.

[212]  H. Beug,et al.  Molecular requirements for epithelial-mesenchymal transition during tumor progression. , 2005, Current opinion in cell biology.

[213]  C. Remuñán-López,et al.  Microencapsulated chitosan nanoparticles for lung protein delivery. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[214]  W. Sadee,et al.  ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. , 2005, Cancer research.

[215]  Amie Y Lee,et al.  Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations , 2005, Oncogene.

[216]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[217]  K. Kataoka,et al.  NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel , 2005, British Journal of Cancer.

[218]  L. Attardi,et al.  The role of apoptosis in cancer development and treatment response , 2005, Nature Reviews Cancer.

[219]  L. Hudson,et al.  Developmental transcription factor slug is required for effective re‐epithelialization by adult keratinocytes , 2005, Journal of cellular physiology.

[220]  K. Soppimath,et al.  pH‐Triggered Thermally Responsive Polymer Core–Shell Nanoparticles for Drug Delivery , 2005 .

[221]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[222]  Steven Sun,et al.  Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. , 2004, Gynecologic oncology.

[223]  N. Bessis,et al.  Immune responses to gene therapy vectors: influence on vector function and effector mechanisms , 2004, Gene therapy.

[224]  M. Goodell,et al.  A distinct "side population" of cells with high drug efflux capacity in human tumor cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[225]  S. Ramaswamy,et al.  Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.

[226]  M. Sayegh,et al.  Immunomodulatory functions of mesenchymal stem cells , 2004, The Lancet.

[227]  Vivek Mittal,et al.  Improving the efficiency of RNA interference in mammals , 2004, Nature Reviews Genetics.

[228]  Moustapha Hassan,et al.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells , 2004, The Lancet.

[229]  T. Minko Drug targeting to the colon with lectins and neoglycoconjugates. , 2004, Advanced drug delivery reviews.

[230]  Alan M Gewirtz,et al.  Progress in the Development of Nucleic Acids Therapeutics for Cancer , 2004, Cancer biology & therapy.

[231]  A. Herrmann,et al.  Reversal of breast cancer resistance protein–mediated drug resistance by tryprostatin A , 2003, International journal of cancer.

[232]  M. Sayegh,et al.  Regulation of Progenitor Cell Fusion by ABCB5 P-glycoprotein, a Novel Human ATP-binding Cassette Transporter* , 2003, Journal of Biological Chemistry.

[233]  Dana Carroll,et al.  Enhancing Gene Targeting with Designed Zinc Finger Nucleases , 2003, Science.

[234]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[235]  J. Pérez-Pomares,et al.  Epithelial–mesenchymal transitions: A mesodermal cell strategy for evolutive innovation in Metazoans , 2002, The Anatomical record.

[236]  A. Balmain,et al.  Metastasis is driven by sequential elevation of H-ras and Smad2 levels , 2002, Nature Cell Biology.

[237]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[238]  D Guthrie,et al.  Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[239]  G. Berx,et al.  The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. , 2001, Molecular cell.

[240]  I. Weissman,et al.  The Role of Apoptosis in the Regulation of Hematopoietic Stem Cells , 2000, The Journal of experimental medicine.

[241]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[242]  A. S. Conner,et al.  Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo , 1996, The Journal of experimental medicine.

[243]  P. Nowell The clonal evolution of tumor cell populations. , 1976, Science.

[244]  J. Vadgama,et al.  Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFκB signaling. , 2015, Anticancer research.

[245]  Yu Zhang,et al.  Anti-ABCG2 monoclonal antibody in combination with paclitaxel nanoparticles against cancer stem-like cell activity in multiple myeloma. , 2014, Nanomedicine.

[246]  Yi Yan Yang,et al.  Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells. , 2014, Biomaterials.

[247]  Yang Liu,et al.  Cancer stem cell therapy using doxorubicin conjugated to gold nanoparticles via hydrazone bonds. , 2014, Biomaterials.

[248]  M. Huang,et al.  Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling. , 2013, Cancer research.

[249]  S. Ryter,et al.  Autophagy in human health and disease. , 2013, The New England journal of medicine.

[250]  D. Cao,et al.  The origin of cancer stem cells. , 2012, Frontiers in bioscience.

[251]  Liwu Fu,et al.  Targeting cancer stem cells: a new therapy to cure cancer patients. , 2012, American journal of cancer research.

[252]  Tzong-Shiue Yu,et al.  A restricted cell population propagates glioblastoma growth after chemotherapy , 2012 .

[253]  R. Elble,et al.  The role of cancer stem cells in relapse of solid tumors. , 2012, Frontiers in bioscience.

[254]  Qiang Zhang,et al.  The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles. , 2012, Biomaterials.

[255]  C. Figdor,et al.  Targeting nanoparticles to dendritic cells for immunotherapy. , 2012, Methods in enzymology.

[256]  菊繁 吉謙 TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells , 2012 .

[257]  Zhijian Wu,et al.  Effect of genome size on AAV vector packaging. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[258]  P. Linsley,et al.  Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application , 2010, Nature Reviews Drug Discovery.

[259]  Jayanth Panyam,et al.  The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. , 2010, Biomaterials.

[260]  V. Torchilin,et al.  Environment-responsive multifunctional liposomes. , 2010, Methods in molecular biology.

[261]  R. Kizek,et al.  Matrix metalloproteinases. , 2010, Current medicinal chemistry.

[262]  Michael Karin,et al.  Is NF-κB a good target for cancer therapy? Hopes and pitfalls , 2009, Nature Reviews Drug Discovery.

[263]  H. Simon,et al.  Autophagy in cancer and chemotherapy. , 2009, Results and problems in cell differentiation.

[264]  M. Vemuri,et al.  Regulatory networks in stem cells , 2009 .

[265]  S. Sell History of Cancer Stem Cells , 2009 .

[266]  Rolf Bjerkvig,et al.  Opinion: the origin of the cancer stem cell: current controversies and new insights. , 2005, Nature reviews. Cancer.

[267]  Mark E. Davis,et al.  PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. , 2004, European journal of cell biology.

[268]  A. Maitra,et al.  Urological Survey UROLOGICAL ONCOLOGY: PROSTATE CANCER Hedgehog Signalling in Prostate Regeneration, Neoplasia and Metastasis , 2005 .

[269]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[270]  L. Doyle,et al.  Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. , 2000, Cancer research.

[271]  C. Pabo,et al.  DNA recognition by Cys2His2 zinc finger proteins. , 2000, Annual review of biophysics and biomolecular structure.

[272]  E. Hay An overview of epithelio-mesenchymal transformation. , 1995, Acta anatomica.